维思通与卓菲治疗精神分裂症的临床对照分析
 |
| 第1页 |
参见附件(1254KB，2页)。
[摘要] 目的:通过分析合资维思通与国产卓菲治疗精神分裂症的临床效果,根据家境和个体情况选取药物。方法:将70例精神分裂症患者随机分为两组,经8周治疗,以CCMD-3精神分裂症的诊断标准、PANSS评定疗效,TESS评定副作用。结果:两组治疗后PANSS评分与治疗前比较,均有显著性差异;治疗后随治疗时间延长而下降,副作用少,说明两药治疗精神分裂症效果显著。结论:维思通疗效比卓菲好,起效快;不良反应卓菲比维思通高;但两者的疗效和副作用比较均无显著性差异,而价格有差别。临床可根据患者经济状况和个体差异来选择使用。
[关键词] 精神分裂症;维思通;卓菲;疗效
[中图分类号] R749.3[文献标识码]A [文章编号]1673-7210(2009)07(c)-062-02
Clinical control study of Weisitong and Zhuofei on schizophrenia
LUO Laixing
(The Second People's Hospital of Huizhou, Huizhou516001, China)
[Abstract] Objective: To discuss the clinical effect of joint-stock Risperidone(Weisitong) and domestic Risperidone(Zhuofei) on schizophrenia. The choosing of the two medicaments was based on the family financial situation and individual difference. Methods: 70 patients with schizophrenia were randomly divided into two groups, after 8 weeks of treatment, all the patients were selected in accordance with the CCMD-3 diagnosis standard ......
您现在查看是摘要介绍页，详见PDF附件(1254KB，2页)。